The behavioral rehabilitation market is projected to reach US$ 540.84 million by 2028 from US$ 350.63 million in 2021; it is estimated to grow at a CAGR of 6.4% from 2021 to 2028.
Drug manufacturers play a critical role in introducing new products to cope with the global market’s demands. For instance, in May 2021, Lybalvi (olanzapine and samidorphan), an atypical antipsychotic medication developed by Alkermes, Inc., an Ireland-based company, received the Food and Drug Administration (FDA) approval to treat adults with schizophrenia and adults with bipolar I disorder. Such active participation of the global market players associated with the market is expected to drive the market.
Based on treatment, the behavioral rehabilitation market is segmented into drugs, counseling, and therapy services. The counseling and therapy services segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR in the market during the forecast period.
Based on healthcare setting, the behavioral rehabilitation market is segmented into anxiety disorders, mood disorders, substance abuse disorders, personality disorders, and attention deficit disorders. The anxiety disorders segment held the largest market share in 2021 and is anticipated to register the highest CAGR in the market during the forecast period.
Based on the healthcare setting, the behavioral rehabilitation market is segmented into outpatient behavioral rehabilitation, inpatient behavioral rehabilitation, and residential behavioral rehabilitation. The outpatient behavioral rehabilitation segment held the largest market share in 2021 and is anticipated to register the highest CAGR in the market during the forecast period.
National Institute on Drug Abuse, Nanalyze, and European Commission are among the primary and secondary sources referred to while preparing the report on the behavioral rehabilitation market.
Our reports have been used by over 10K customers, including:
The report considers the present scenario of the global mental wellness market and its market dynamics for 2022?2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent...
South Korea In-depth PESTLE Insights Summary This PESTLE country analysis report on South Korea provides a holistic view of the country, with insightful analysis of current and future issues, supplemented with relevant quantitative data to support trend analysis. Synopsis -...
Australia In-depth PESTLE Insights Summary This PESTLE country analysis report on Australia provides a holistic view of the country, with insightful analysis of current and future issues, supplemented with relevant quantitative data to support trend analysis. Synopsis -...
The blood brain barrier technologies market is expected to reach US$ 5,101.94 million by 2028 from US$ 1,041.05 million in 2021; it is estimated to register a CAGR of 25.5% from 2021 to 2028. Growing prevalence of neurological disorders, and increasing geriatric population and rising prevalence of age-associated neurological disorders are...
104 pages •
By Infiniti Research Limited
• May 2018
About CNS therapeutics CNS therapeutics cater to CNS disorders that affect the structure or function of the brain or spinal cord such as Parkinson’s disease, epilepsy, Alzheimer’s disease, anxiety, depression, and bipolar disorders. Technavio’s analysts forecast the Global CNS therapeutics market to grow at a CAGR...
The global narcolepsy market is expected to reach US$ 4,537.9 Mn in 2027 from US$ 2,026.8 Mn in 2018. The market is estimated to grow with a CAGR of 9.5% from 2019-2027. The growth of the narcolepsy market is primarily attributed to the rising prevalence of sleep related neurological disorders, emerging local pharmaceutical and biopharmaceutical...
Mental Health
APAC
World
United States
Health Expenditure
Drug Approval
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.